What is driving the oversold reading for ABT.SW stock?

The oversold reading (RSI 4.70) stems from rapid selling into the year low area, thin SIX liquidity (volume 40.00), and negative short-term momentum (MACD -0.76). Low volume amplifies price moves, creating an extreme RSI that favors short-term mean reversion.

What short-term price target should traders watch for an ABT.SW bounce?

For a confirmed bounce we watch **CHF106.00** as the first short-term target and **CHF109.55** (Meyka quarterly model) as a secondary target. Confirmation requires a volume-backed green candle or RSI >30.00.

How does valuation affect the ABT.SW outlook?

Valuation is elevated: **PE 34.84**, price-to-sales **5.09**, and price-to-book **4.45**. Strong cash flow and low leverage help, but high multiples limit upside without earnings improvement or positive catalysts.

How reliable are Meyka AI's price forecasts for ABT.SW?

Meyka AI's forecast model projects short- and medium-term prices but these are model-based projections and not guarantees. Use them with technical confirmation and risk controls; the model shows quarterly upside (+9.55%) and mixed monthly risk (-12.70%).

CH Stocks

ABT.SW Abbott Laboratories CHF100.00 pre-market 19 Feb 2026: Oversold bounce

ByHuzaifa Zahoor February 19, 2026

ABT.SW stock opens pre-market at CHF100.00 on 19 Feb 2026 with an RSI of 4.70, an extreme oversold reading that often precedes a short-term bounce. Volume is thin at 40.00 shares on SIX so far, so any recovery may be fragile. Traders should watch the 50-day average CHF99.24 and the 200-day CHF102.26 for early confirmation. This report lays out valuation, technical triggers, Meyka AI grade, and a concise trade plan for an oversold-bounce approach.